Although the clinical outcomes for patients with HER2-positive BC have dramatically improved due to trastuzumab and other anti-HER2 therapies, notwithstanding appropriate treatment, it remains that 15–20% of HER2-positive patients still experience relapse of the disease within 5 years5–7. Here, ERBB2 is linked to breast cancer.